Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months.

"Declaration of competing interest M.W. received funding for research from 10.13039/501100001659Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Deutsche Gesellschaft für Pneumologie, European Respiratory Society, Marie Curie Foundation, Else Kröner Fresenius Stiftung, Capnetz Stiftung, International Max Planck Research School, Actelion, 10.13039/100004326Bayer Health Care, Biotest, 10.13039/100008349Boehringer Ingelheim, Noxxon, Pantherna, Quark Pharma, Silence Therapeutics, Takeda Pharma, Vaxxilon, and for lectures and advisory from Actelion, 10.13039/100006396Alexion, Aptarion, Astra Zeneca, 10.13039/100004326Bayer Health Care, Berlin Chemie, Biotest, 10.13039/100008349Boehringer Ingelheim, 10.13039/100007560Chiesi, Glaxo Smith Kline, Insmed, 10.13039/100004336Novartis, Teva and Vaxxilon. T.Z. received funding for research from Bundesministerium für Bildung und Forschung, Else Kröner-Fresenius Stiftung and Gesellschaft für 10.13039/100011259Internationale Zusammenarbeit."

"Funding The Pa-COVID-19 study is supported by grants from the 10.13039/501100017268Berlin Institute of Health (BIH) and the 10.13039/501100002347German Federal Ministry of Education and Research (01KX2021 and 01KI20160A). The section you refere report conflict of interest / competing interests."

"This analysis included participants of the Pa-COVID-19 study at Charité Universitätsmedizin Berlin, an academic tertiary care medical centre. Pa-COVID-19 is a prospective observational study registered at the German clinical trials registry (DRKS 00021688) aiming to provide a platform for clinical characterisation of acute and post-acute COVID-19 []. The study was approved by Charité ethical committee (EA2/066/20). Patients with a positive SARS-CoV-2 PCR test are offered participation at first contact during hospitalization or follow-up anytime after disease onset and included after giving informed consent. Exclusion criteria are refusal to participate by the patient or legal representative, or a patient condition making additional blood sampling impossible. Medical data is collected prospectively in a purpose-built database. Due to the explorative design of the Pa-COVID-19 study and study initiation at the early beginning of the pandemic, no specific endpoints were defined a priori, and no sample size based on specific outcomes was calculated."